BELIEVE: Phase III Study of Luspatercept vs Placebo in Beta-Thalassemia

December 1-4, 2018; San Diego, California

Transfusion-dependent adults with beta-thalassemia who received luspatercept were more likely to achieve clinically meaningful reductions in transfusion burden compared with placebo.

Format: Microsoft PowerPoint (.ppt)
File Size: 196 KB
Released: December 4, 2018

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AbbVie
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Incyte
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs
Seattle Genetics
Takeda Oncology

Related Content

From Clinical Care Options, Zofia Piotrowska, MD, MHS, and Stephen V. Liu, MD, review key data from studies of lung cancer treatment presented at ASCO 2020

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 25, 2020 Expired: September 24, 2021

Commentary from Jeff Sharman, MD, on noncovalent BTK inhibitors in patients with CLL and progression on currently available BTK inhibitors, from Clinical Care Options (CCO)

Jeff P. Sharman, MD Released: September 25, 2020

Expert commentary featuring recommendations on preserving continuity of care and ensuring safety for patients with advanced breast cancer during the COVID-19 pandemic

Hope S. Rugo, MD Released: September 25, 2020

Gain key clinical insights fast, with this short slideset from CCO on lung cancer data presented at 2020 ASCO

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Released: September 25, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue